A systematic review of three decades of research concludes that photodynamic inactivation — the use of light-activated photosensitizer molecules to generate reactive oxygen species — is a potent, broad-spectrum antiviral strategy against enveloped viruses in laboratory and ex vivo settings, but that the clinical evidence remains thin, fragmented and largely confined to blood product decontamination and localized lesions. The review, published in International Microbiology by Mohammad Sina Alikhani and colleagues, screened 242 records and included 30 studies published between January 1990 and April 2026: 22 in vitro or ex vivo experiments, four animal studies and just four clinical investigations. Because of pronounced heterogeneity in viral targets, photosensitizers, light parameters and outcome measures, the authors pooled no data quantitatively and instead synthesized findings narratively under PRISMA 2020 guidelines.
The central mechanism is shared across all applications. A photosensitizer — a molecule that absorbs light of a specific wavelength — is exposed to matching illumination in the presence of molecular oxygen, producing reactive oxygen species such as singlet oxygen that inflict oxidative damage on viral lipids, proteins and nucleic acids. Unlike conventional antivirals that inhibit a single molecular target, this multi-target oxidative assault makes the development of resistance theoretically less likely. The review explicitly separates two applications that are often conflated: photodynamic inactivation, or PDI, which destroys viruses in ex vivo matrices such as blood products, water and surfaces, and photodynamic therapy, or PDT, which treats viral infections or lesions in living organisms. The distinction matters because the translational prospects of the two are very different.
The most striking pattern in the dataset is structural. Enveloped viruses — those carrying a host-derived lipid membrane studded with glycoproteins — proved consistently susceptible to photodynamic killing. Studies of HIV-1, for example, showed that methylene blue at 1 micromolar concentration, activated with 620–670 nm light, achieved greater than 6.3 log10 reductions in infectivity within ten minutes, with cross-linking of the gp120 envelope glycoprotein, structural alterations of the p24 capsid, degradation of viral RNA and complete inhibition of reverse transcriptase, all strictly dependent on light exposure. The silicon phthalocyanine Pc4 achieved at least 5.5 log10 reductions of HIV in red blood cell concentrates at 670–680 nm with 18–40 J/cm², with hemolysis below 1 percent after extended storage.
Similar potency emerged across other enveloped families. Vesicular stomatitis virus, a common surrogate for enveloped RNA viruses, was reduced by more than 5 log10 in every one of seven included studies, using photosensitizers ranging from methylene blue and aluminum phthalocyanine tetrasulfonate to fullerenes and dimethylmethylene blue, at light doses from 1 to 120 J/cm². Mechanistic work identified singlet oxygen as the dominant damaging species through oxygen-dependence experiments and quenching studies. Notably, one study found that lower fluence rates — 10 versus 50 mW/cm² at matched total fluence — were paradoxically associated with greater VSV inactivation, but the authors of that study rejected simple oxygen depletion as an explanation and proposed alternative photochemical pathways, and the effect has not been consistently replicated. Strategies to protect blood cells during treatment also advanced: combining dimethylmethylene blue with quinacrine achieved more than 5 log VSV inactivation while reducing hemolysis from roughly 20 percent to 5 percent.
Coronavirus data, though limited to three studies, followed the same envelope-centric logic. Hydrophobic Rose Bengal alkyl esters activated at 520 nm with 6 J/cm² showed sub-nanomolar effective concentrations against SARS-CoV-2 in Vero cells, with exceptionally high selectivity indices — but no activity against non-enveloped viruses, implicating lipid membrane damage as the dominant mechanism. Methylene blue at 1 micromolar with 660 nm light at 1 J/cm² produced greater than four log10 reductions in SARS-CoV-2 pseudovirus transduction, with the combined treatment showing synergy with UV-C and oxygen dependence supporting a type II photochemical mechanism. The ruthenium compound TLD-1433, illuminated at 525 nm with 45 J/cm², inactivated more than 90 percent of human coronavirus OC-43 within seconds at low nanomolar concentrations, acting chiefly through lipid peroxidation — although its performance declined markedly in protein-rich or turbid matrices.
Herpesviruses and mosquito-borne enveloped RNA viruses showed comparable vulnerability. Cationic vinyl-substituted porphyrins achieved greater than 99 percent plaque reduction of HSV-1 at 0.5–1 micromolar with 5 J/cm² at 630 nm, with efficacy tracking the number of hydrophobic vinyl substituents. Zinc phthalocyanine conjugated to IgY antibodies completely inactivated bovine herpesvirus 1 in artificially infected bovine semen while preserving sperm motility, and TLD-1433 and Rose Bengal derivatives rapidly inactivated Zika and Chikungunya viruses at nanomolar concentrations. By contrast, non-enveloped viruses proved far more stubborn. Adenovirus type 5 and mammalian orthoreovirus required micromolar TLD-1433 concentrations and prolonged irradiation of up to 720 J/cm² to yield measurable infectivity reductions, and rotaviruses needed riboflavin activated by simulated sunlight at cumulative fluences up to 100 J/cm² in water. The dense protein capsids of these viruses lack the lipid membrane that photosensitizers attack most efficiently, though the review cautions that envelope status is not a universal rule — matrix composition, photosensitizer localization and aggregation state may matter at least as much.
The clinical evidence base is small and mixed. One randomized crossover trial in twelve healthy volunteers who received methylene blue-treated plasma reported no serious adverse events or significant laboratory changes, providing early human safety data for pathogen-reduced plasma — but not evidence that antiviral PDT is safe or effective when administered to infected patients. A pediatric case report described complete resolution of HSV-1–associated erythema multiforme major within seven days after methylene blue-mediated PDT with 660 nm LED light at 10 J/cm². The review also cites limited studies of localized lesions, including ALA-PDT for HPV-related cervical lesions with reported regression rates of 90–95 percent and HPV clearance of 67.5 percent, combination PDT after excision of condylomata with zero recurrence versus 33.3 percent with trichloroacetic acid, and preliminary intranasal PDT for mild COVID-19 with PCR negativity within 4–7 days. These reports are heterogeneous and frequently small, so they should be read as signals warranting further trials rather than established efficacy.
Several caveats temper the safety picture. Methylene blue treatment of plasma, while efficiently destroying enveloped viruses, reduced factor VIII activity by 30–36 percent and fibrinogen by 15–40 percent, and the balance between viral kill and preservation of labile blood components remains a central engineering challenge. Organic matter — serum proteins, mucin, wastewater solids — scavenges reactive oxygen species and attenuates efficacy, meaning protocols must be tailored to each viral target and matrix. Photophysical parameters are chronically underreported: risk of bias assessment found incomplete light parameter reporting in 10 of 30 studies and lack of blinding in 14, although 18 studies rated low risk of bias in at least four of six domains and sensitivity analyses did not change the main conclusion about envelope-dependent susceptibility. The review also was not prospectively registered, a limitation the authors acknowledge may introduce selective reporting risk, mitigated by a priori definitions of all search and eligibility criteria.
The review’s most consequential boundary statement is stark: current evidence does not support conventional PDT as a clinically feasible treatment for systemic viremia. Treating viruses circulating in the bloodstream would require whole-body irradiation or invasive light delivery to internal organs, neither feasible nor safe with current technology, and systemic photosensitizer administration risks generalized phototoxicity. All efficacy claims therefore apply strictly to in vitro models, localized accessible infections and ex vivo blood product processing. The authors point to possible future directions — extracorporeal light-delivery devices, nanoparticle-based photosensitizer carriers, type I photosensitizers that generate radical species with reduced oxygen dependence for hypoxic tissues, and combinations with antivirals such as acyclovir — but stress that none has been clinically validated. They also note that some drug-resistant strains, including acyclovir-resistant HSV-1, may resist conventional photosensitizers. Their bottom line is that the most realistic antiviral applications remain exactly where the strongest evidence already sits: decontaminating blood products and treating localized mucocutaneous infections, with rigorous clinical trials still needed before broader claims can be made.
Subject of Research: Antiviral efficacy and translational limits of photodynamic inactivation and photodynamic therapy against viral pathogens
Article Title: Photodynamic inactivation and photodynamic therapy for viral pathogens: a systematic review of antiviral efficacy, mechanisms, and translational boundaries
Article References: Alikhani, M. S., Farmani, A., Teimoori, A., Dosti-Irani, A., Sadrzadeh-Afshar, M.-S., & Fekrazad, R. (2026). Photodynamic inactivation and photodynamic therapy for viral pathogens: a systematic review of antiviral efficacy, mechanisms, and translational boundaries. International Microbiology. https://doi.org/10.1007/s10123-026-00915-z
Image Credits: AI Generated
DOI: 10.1007/s10123-026-00915-z
Keywords: photodynamic inactivation, photodynamic therapy, photosensitizers, enveloped viruses, methylene blue, reactive oxygen species, blood product decontamination, SARS-CoV-2, HIV, herpesviruses, systematic review, antiviral
News Source: Kristina Jarvis. (October 23, 2026). Light-Activated Drugs Kill Enveloped Viruses, but Clinical Uses Stay Narrow, Review Finds. Scienmag.
